

























Abstract:Genomic prediction of drug resistance in Mycobacterium tuberculosis is often hindered by complex epistatic interactions and variable sequencing quality. We present the Interpretable Variant-Aware Multi-Path Network (VAMP-Net), a novel architecture addressing these challenges through a dual-pathway approach. Path-1 utilizes a Set Attention Transformer to model permutation-invariant variant sets and capture epistatic dependencies, while Path-2 employs a 1D-CNN to analyze VCF quality metrics for adaptive confidence scoring. Evaluated on four critical anti-TB drugs, VAMP-Net significantly outperforms baseline CNN and MLP models, achieving accuracies > 95% and AUCs around 0.97 for Rifampicin and Rifabutin. Feature attribution analysis via Integrated Gradients successfully recovered canonical targets (rpoB, embB, katG) and discovered high-impact novel loci. Functional enrichment confirmed these novel variants constitute non-random metabolic modules (p=0.00239) centered on cell-wall remodeling. Furthermore, systematic ablation of the Quality-Aware pathway demonstrates that the model performs a learned "integrated audit," prioritizing the Fraction of Supporting Reads and relative confidence over raw depth to mitigate technical noise. This dual-layer interpretability, bridging genomic pathogenicity with technical reliability, establishes a new paradigm for robust, auditable, and clinically actionable resistance prediction, positioning VAMP-Net as an important tool for both diagnostic classification and mechanistic discovery in clinical genomics.
| Subjects: | Machine Learning (cs.LG) |
| Cite as: | arXiv:2512.21786 [cs.LG] |
| (or arXiv:2512.21786v2 [cs.LG] for this version) | |
| https://doi.org/10.48550/arXiv.2512.21786 arXiv-issued DOI via DataCite |
From: Aicha Boutorh [view email]
[v1]
Thu, 25 Dec 2025 21:28:54 UTC (1,906 KB)
[v2]
Sat, 25 Apr 2026 18:11:06 UTC (10,996 KB)
此内容由惯性聚合(RSS阅读器)自动聚合整理,仅供阅读参考。 原文来自 — 版权归原作者所有。